NEWS HIGHLIGHTSMedia Articles Related to Cardura XL (Doxazosin)
Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Source: MedicineNet doxazosin mesylate Specialty [2012.02.29]
Title: Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Category: MedicineNet Quiz
Created: 2/7/2012 3:29:00 PM
Last Editorial Review: 2/29/2012 6:25:09 PM
Cialis® For Once Daily Use Now FDA-Approved To Treat Men With Signs And Symptoms Of Benign Prostatic Hyperplasia (BPH) And Men With Both ED And BP
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2011.10.08]
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH)...
Cialis (Tadalafil) Approved For Benign Prostatic Hyperplasia Treatment, USA
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2011.10.07]
Tadalafil (Cialis) has been approved by the FDA (Food and Drug Administration) for the treatment of BPH (benign prostatic hyperplasia) signs and symptoms - a condition in which the prostate gland enlarges. It has also been approved for the treatment of simultaneous BPH and ED (erectile dysfunction). Since 2003, the medication has been on the market legally in the USA for ED treatment...
Benign Prostatic Hyperplasia
Source: MedicineNet Saw Palmetto Specialty [2008.06.23]
Title: Benign Prostatic Hyperplasia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 6/23/2008
Published Studies Related to Cardura XL (Doxazosin)
Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. [2011.09]
OBJECTIVE: To compare the efficacy of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg and tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)... CONCLUSION: In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: randomized controlled trial. [2011.08.12]
Alpha-blockers have been established as medical expulsive therapy for urolithiasis. We aimed to assess the effect of tamsulosin and doxazosin as adjunctive therapy following SWL for renal calculi... The side-effects of these agents are common and should be weighted against the benefits of their usage.
An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. [2011.07]
This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)...
[Kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin for the treatment of chronic epididymitis]. [2010.12]
OBJECTIVE: To study the clinical effects of kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin in the treatment of chronic epididymitis... CONCLUSION: Either doxazosin alone or kidney-tonifying and dampness-expelling Chinese herbal decoction combined with doxazosin is obviously effective on chronic epididymitis, but the combined medication produces an even better efficacy.
[Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS]. [2010.09]
OBJECTIVE: To determine the efficacy and safety of a diuretic agent, frusemide, combined with doxazosin in the treatment of nocturia in patients with benign prostate hyperplasia / lower urinary tract symptoms (BPH/LUTS)... CONCLUSION: Four-week treatment with frusemide plus doxazosin was safe and effective for nocturia in patients with BPH/LUTS.
Clinical Trials Related to Cardura XL (Doxazosin)
The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine [Recruiting]
Human Laboratory Trial of Doxazosin for Cocaine Dependence: Accumulating evidence implicates
noradrenergic (NE) systems in mediating the effects of stimulants (1-8). Mice lacking NE £\
- 1 receptor mice show reduced sensitivity to cocaine and amphetamine (8, 9). Local depletion
of prefrontal cortex (PFC) NE reduced rewarding effects of amphetamine and reduced
amphetamine-induced dopamine (DA) release in the PFC and accumbens (7), suggesting that PFC
NE contributes to the rewarding effects of stimulants. Treatment with the NE Ą-1 antagonist
prazosin has been shown to antagonize a variety of effects produced by cocaine and
amphetamine. In rats, prazosin (1-2 mg/kg) significantly attenuated the locomotor activating
effects produced by cocaine (10-12) and for amphetamine (4, 13, 14). Similar findings have
been observed for the discriminative stimulus effects produced by cocaine and amphetamine in
mice (15) and for food-maintained responding in pigeons (16). More recently, prazosin (0. 3
mg/kg) reduced reinstatement of extinguished cocaine-seeking behavior in rats without
affecting responding for food, suggesting that prazosin my blunt the motivational effects of
drug cues (5). Clinical Experience with Alpha-1 Adrenergic Antagonists: Prazosin is a
prototypical antagonist at NE £\-1 receptors. When first released the medication was thought
to produce relaxation of smooth muscles in the vasculature. Since then however it has been
determined that prazosin antagonizes norepinephrine and this mediates the antihypertensive
effect (17). The medication has been assessed extensively for the treatment of hypertension
(18). The initial dose is 1mg two or three times per day. The usual dose range is 6mg/day to
15mg/day, with some patients requiring up to 40mg/day in divided doses. The most common side
effects are: dizziness 10. 3%, headache 7. 8%, drowsiness 7. 6%, lack of energy 6. 9%, weakness
6. 5%, palpitations 5. 3%, and nausea 4. 9%. In most instances side effects have disappeared
with continued therapy or have been tolerated with no decrease in dose of drug. More
recently, prazosin has been successfully used to treat post traumatic stress disorder (19,
20). For this indication, prazosin was initiated at 1mg at bedtime and increased as needed
to control symptoms to up to 15mg at bedtime by day 28. This approach resulted in no change
in systolic and diastolic blood pressure compared to pretreatment measurements. Several
subjects reported transient dizziness upon standing (9/14 in the prazosin group and 6/15 in
the placebo group), but none reported syncope. Prazosin has a relatively short elimination
half-life of 3. 5 h (21). Longer-lasting cogeners (e. g. terazosin and doxazosin) are
available, but there is no experience using these medications as treatments for cocaine
dependence. The purpose of this study is to evaluate the effects of doxazosin on the
cardiovascular and subjective effects of cocaine in a human laboratory study. Doxazosin was
selected because it has a longer elimination half-life (22h) compared to terazosin (12h).
The side-effect profile of doxazosin closely resembles that of prazosin.
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) [Recruiting]
The purpose of this study is to determinate the effect of a pre-treatment with doxazosin, a
alpha1-adrenergic receptor blocker, on the pharmacodynamics and pharmacokinetics of
3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The investigators hypothesize that
doxazosin will attenuate the cardiovascular and subjective response to MDMA.
The Efficacy of Doxazosin for Cocaine Users [Recruiting]
Doxazosin, an alpha 1-adrenergic receptor may play an important role in cocaine addiction in
human. This study will evaluate the effectiveness of doxazosin in preventing drug relapse
among cocaine addicts.
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) [Recruiting]
OAB occurs in approximately 50% to 75% of men with BPO and up to 38% of men with BPO
continue to suffer from OAB after relief the obstruction. Symptoms of OAB are more bothersome
than the voiding complaints of slow stream and hesitancy. However, the patients with both
BPO and OAB are often not treated with muscarinic receptor antagonists due to concern that
they will experience acute urinary retention.
Tolterodine is a potent and pure muscarinic receptor antagonist that was developed
specifically for the treatment of overactive bladder. Recently, studies revealed that
tolterodine was effective, safe and well tolerated in adults with OAB and urodynamically
confirmed BPO. However, the optimal dosage of antimuscarinic for the treatment of OAB
coexisting BPO was not yet fully assessed. In real clinical situation, some patients
complain voiding difficulty after addition of antimuscarinics and want to stop
antimuscarinics. It is probable that a lower dosage of antimuscarinics combined with
alpha-adrenergic antagonists can be used safely in OAB patients with BOO, with the same
efficacy.
This study is designed to investigate the optimal doses of tolterodine SR in combination
with doxazosin in men with both BOO and OAB based on efficacy, safety, and tolerability.
Pharmacogenetics of Doxazosin for Cocaine Dependence [Not yet recruiting]
Doxazosin, an alpha 1-adrenergic receptor may play an important role in cocaine addiction in
human. This study will evaluate to what extend the prospective screening for catecholamine
related polymorphisms for alpha 1 NE receptor/transporter, COMT and DBH as main targets
predict the treatment efficacy of doxazosin for cocaine-using behavior.
|